StemCells announced dosing of the first high-dose patient in the company's Phase 1,2 clinical trial in dry age-related macular degeneration.The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with 1M HuCNS-SC cells. The first four patients each received a dose of 200K cells. An independent Data Safety Monitoring Committee conducted a review of the trial data to date, and found no safety issues to preclude the trial from proceeding to the high dose.